Results 211 to 220 of about 16,509,108 (311)

Trends in 25 years of antihypertensive agent utilization in Croatia – an alert for scientific community and healthcare providers

British Journal of Clinical Pharmacology, EarlyView.
Aims Hypertension is a leading modifiable risk factor for cardiovascular mortality worldwide. This study aimed to evaluate 25‐year trends in antihypertensive agent (AHA) utilization in Croatia between 2000 and 2024. Methods We conducted a national, population‐based analysis using IMS and IQVIA pharmaceutical databases.
Andrej Belančić, Marta Kučan Štiglić, Ana Jelaković, Bojan Jelaković, Dinko Vitezić   +4 more
wiley   +1 more source

Brain Health and Traumatic Brain Injury (TBI): Relationship Between Brain Care Score and Disability in Subacute-Long Term TBI. [PDF]

Am J Lifestyle Med
Sakayan M, Paulino MT, Fang AS, Joyner C, Tovar-Vargas S, Kapoor A, Conrad A, Lopez M, Izzy S, Bartell SM, Nguyen DV, Mapstone M, Boden-Albala B, Chen PM.   +13 more
europepmc   +1 more source

Cost–benefit analysis of screening programme for diabetic retinopathy in Bulgaria

British Journal of Clinical Pharmacology, EarlyView.
Aims Late‐diagnosed diabetic retinopathy (DR) is difficult and expensive to treat. Screening programmes can identify the disease early and reduce the costs of its future treatment. This study aims to analyse the cost–benefit of screening programmes for DR.
Iva Nenkova, Yoana Lilova, Alexander Oscar, Alina Levi, Maria Kamusheva, Guenka Petrova   +5 more
wiley   +1 more source

Sociodemographic disparities and hospice referral practice patterns among patients with recurrent cervical cancer. [PDF]

Gynecol Oncol Rep
File BH, Rara MR, Nemmani RS, Chang J, Bristow RE.   +4 more
europepmc   +1 more source

Cost‐utility analysis of nusinersen–risdiplam switch in patients with spinal muscular atrophy in Croatia: A discrete event simulation model

British Journal of Clinical Pharmacology, EarlyView.
Introduction In recent years, the treatment of spinal muscular atrophy (SMA), a rare disease, has significantly progressed, improving patients' survival and overall quality of life. However, current SMA treatments are expensive, and some (nusinersen) are very inconvenient for patients.
Andrej Belančić, Ivana Stević, Elvira Meni Maria Gkrinia, Dinko Vitezić, Slobodan Janković   +4 more
wiley   +1 more source

The impact of home- and community-based services on life satisfaction among older adults: evidence from marginal treatment effect framework. [PDF]

Front Public Health
Zhu A, Kong Z, Chen C.
europepmc   +1 more source

Financial toxicity and distress among prostate cancer patients in Lebanon: a cross-sectional study. [PDF]

Front Public Health
Abi Karam M, Mina A, Ghadban E, Azar Z, Khalil J, El Khoury G, El Breidy S, El Hachem C, Saad R, Kassis A, El Khoury R.   +10 more
europepmc   +1 more source

How the HTAR will contribute to a value‐based decision‐making for medicinal products across the EU

British Journal of Clinical Pharmacology, EarlyView.
The European Union Health Technology Regulation 2021/2282 (HTAR) introduces joint assessment of health technologies (including medicinal products and medical devices) across EU Member States. It was signed into law in 2021 and came into full force in January 2025.
Roisin Adams, Michal Stanak
wiley   +1 more source

Differences in patient-centered burdens and economic outcomes based on sociodemographic characteristics and social determinants of health: a scoping review. [PDF]

Front Public Health
D'Angelo S, Kirsch S, Shenkar E, Khavjou O, Giombi K.   +4 more
europepmc   +1 more source